412 related articles for article (PubMed ID: 18207455)
1. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.
Poceta JS; Parsons L; Engelland S; Kripke DF
Sleep Med; 2009 Jan; 10(1):129-33. PubMed ID: 18207455
[TBL] [Abstract][Full Text] [Related]
2. [Concentrations of monoamines and monoamine metabolites in cerebrospinal fluid determined by high-performance liquid chromatography with electrochemical detection].
Yoshino K
No To Shinkei; 1982 Nov; 34(11):1099-106. PubMed ID: 6186264
[TBL] [Abstract][Full Text] [Related]
3. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
[TBL] [Abstract][Full Text] [Related]
4. Circadian changes in CSF dopaminergic measures in restless legs syndrome.
Earley CJ; Hyland K; Allen RP
Sleep Med; 2006 Apr; 7(3):263-8. PubMed ID: 16564215
[TBL] [Abstract][Full Text] [Related]
5. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
Lunardi G; Galati S; Tropepi D; Moschella V; Brusa L; Pierantozzi M; Stefani A; Rossi S; Fornai F; Fedele E; Stanzione P; Hainsworth AH; Pisani A
Parkinsonism Relat Disord; 2009 Jun; 15(5):383-9. PubMed ID: 19010710
[TBL] [Abstract][Full Text] [Related]
6. Analysis of neurotransmitter metabolite concentrations in canine cerebrospinal fluid.
Vaughn DM; Coleman E; Simpson ST; Satjawatcharaphong C
Am J Vet Res; 1988 Aug; 49(8):1302-6. PubMed ID: 2459997
[TBL] [Abstract][Full Text] [Related]
7. Circadian variation of hypocretin-1 (orexin A) in restless legs syndrome.
Baier PC; Göder R; Hallschmid M
Sleep Med; 2009 Feb; 10(2):271; author reply 272. PubMed ID: 19013101
[No Abstract] [Full Text] [Related]
8. Sampling issues of cerebrospinal fluid and plasma monoamines: Investigation of the circadian rhythm and rostrocaudal concentration gradient.
Janssens J; Atmosoerodjo SD; Vermeiren Y; Absalom AR; den Daas I; De Deyn PP
Neurochem Int; 2019 Sep; 128():154-162. PubMed ID: 31034914
[TBL] [Abstract][Full Text] [Related]
9. Narcolepsy in Parkinson's disease.
Haq IZ; Naidu Y; Reddy P; Chaudhuri KR
Expert Rev Neurother; 2010 Jun; 10(6):879-84. PubMed ID: 20518604
[TBL] [Abstract][Full Text] [Related]
10. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.
Yasui K; Inoue Y; Kanbayashi T; Nomura T; Kusumi M; Nakashima K
J Neurol Sci; 2006 Dec; 250(1-2):120-3. PubMed ID: 17005202
[TBL] [Abstract][Full Text] [Related]
11. Restless legs syndrome in Parkinson's disease: a case-controlled study.
Krishnan PR; Bhatia M; Behari M
Mov Disord; 2003 Feb; 18(2):181-5. PubMed ID: 12539212
[TBL] [Abstract][Full Text] [Related]
12. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients.
Carpenter LL; Moreno FA; Kling MA; Anderson GM; Regenold WT; Labiner DM; Price LH
Biol Psychiatry; 2004 Sep; 56(6):418-26. PubMed ID: 15364040
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease.
Asai H; Hirano M; Furiya Y; Udaka F; Morikawa M; Kanbayashi T; Shimizu T; Ueno S
Clin Neurol Neurosurg; 2009 May; 111(4):341-4. PubMed ID: 19097685
[TBL] [Abstract][Full Text] [Related]
14. CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome.
Earley CJ; Hyland K; Allen RP
Mov Disord; 2001 Jan; 16(1):144-9. PubMed ID: 11215576
[TBL] [Abstract][Full Text] [Related]
15. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
16. Treatment enhances ultradian rhythms of CSF monoamine metabolites in patients with major depressive episodes.
Salomon RM; Kennedy JS; Johnson BW; Urbano Blackford J; Schmidt DE; Kwentus J; Gwirtsman HE; Gouda JF; Shiavi RG
Neuropsychopharmacology; 2005 Nov; 30(11):2082-91. PubMed ID: 15856079
[TBL] [Abstract][Full Text] [Related]
17. Hypocretin (orexin) loss in Parkinson's disease.
Fronczek R; Overeem S; Lee SY; Hegeman IM; van Pelt J; van Duinen SG; Lammers GJ; Swaab DF
Brain; 2007 Jun; 130(Pt 6):1577-85. PubMed ID: 17470494
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of drug-induced changes in dopamine and serotonin metabolite concentrations in the CSF of the rat.
Mignot E; Laude D; Elghozi JL
J Neurochem; 1984 Mar; 42(3):819-25. PubMed ID: 6198472
[TBL] [Abstract][Full Text] [Related]
19. [A study of clinical pictures and monoamine metabolism of Gilles de la Tourette syndrome].
Takano K; Ishiguro T
Seishin Shinkeigaku Zasshi; 1993; 95(1):1-29. PubMed ID: 7685527
[TBL] [Abstract][Full Text] [Related]
20. [Monoamines, monoamine metabolites, neuron specific enolase and myelin basic protein concentrations in cerebrospinal fluid of resuscitated patients].
Takahashi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1997 Feb; 17(1):7-16. PubMed ID: 9134533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
